Programs

Programs

Scroll To Explore

Proprietary programs

  • EP4R antagonist for immuno-oncology

    Discover
  • mGluR4/7/8 positive allosteric modulator for Parkinson’s disease

    Discover
  • NPFFR small molecule antagonist to combat the opioid crisis

    Discover
  • PAR2 negative allosteric modulator for rare inflammatory diseases

    Discover
  • First-in-class anti-GPCR antibody for immuno-oncology

    Discover
  • MC4R pharmacochaperone for the treatment of early onset obesity

    Discover

Pharma partnerships

  • Best-in-class treatment for immuno-oncology

    Discover
  • Orphan GPCRs for Central Nervous System (CNS) disease area

    Discover
  • New GPCRs target identification and validation

    Discover

Asset-centric companies

  • First-in-class CXCR4 agonist to control auto-immune diseases

    Discover
  • Sema3A fusion protein for immuno-oncology

    Discover
  • First-in-class mGluR3 PAM for Parkinson’s disease

    Discover
  • EXITED – FIND Therapeutics 2020

    Discover
  • EXITED - acquired by Lundbeck 2018

    Discover
  • EXITED - out-licensed to Merck 2017

    Discover
Partnerships
Adenosine A2AR antagonist